Diagenode

The Inhibition of the Histone Methyltransferase EZH2 by DZNEP or SiRNA Demonstrates Its Involvement in MGMT, TRA2A, RPS6KA2, and U2AF1 Gene Regulation in Prostate Cancer.


El Ouardi D, Idrissou M, Sanchez A, Penault-Llorca F, Bignon YJ, Guy L, Bernard-Gallon D

In France, prostate cancer is the most common cancer in men (Bray et al., 2018). Previously, our team has reported the involvement of epigenetic factors in prostate cancer (Ngollo et al., 2014, 2017). The histone 3 lysine 27 trimethylation (H3K27me3) is a repressive mark that induces chromatin compaction and thus gene inactivation. This mark is regulated positively by the methyltransferase EZH2 that found to be overexpressed in prostate cancer.

Tags
Antibody

Share this article

Published
December, 2019

Source

Products used in this publication

  • Antibody ChIP-seq grade icon
    C15410039-50
    EZH2 polyclonal antibody
  • Antibody ChIP-seq grade icon
    C15410195
    H3K27me3 polyclonal antibody - ChIP-seq Grade
  • RFX5-polyclonal-antibody-diagenode
    C15410206
    Rabbit IgG

Events

  • EpiChrom
    Umea Sweden
    Feb 27-Feb 28, 2020
 See all events

News

 See all news


The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.



  ABOUT SSL CERTIFICATES

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics